Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19854074 | 0.95 | RAB9A (0.39) | RAB9AFFAR4GPR119BCHEPTPN11 | |
| SCHEMBL19853901 | 0.91 | RAB9A (0.46) | RAB9AGPR119P2RY14RARB | |
| SCHEMBL19854628 | 0.91 | RARB (0.40) | RAB9AESR1FFAR4GPR119P2RY14 | |
| SCHEMBL19855905 | 0.89 | RAB9A (0.48) | RAB9AGPR119BCHE | |
| SCHEMBL19854024 | 0.89 | RAB9A (0.38) | RAB9AESR1FFAR4GPR119P2RY14 | |
| SCHEMBL19854022 | 0.87 | SPHK1 (0.38) | FFAR4P2RY14 | |
| SCHEMBL19854036 | 0.87 | SPHK1 (0.39) | FFAR4 | |
| SCHEMBL19854633 | 0.87 | SPHK1 (0.39) | FFAR4 | |
| SCHEMBL19856040 | 0.86 | RAB9A (0.46) | RAB9AGPR119 | |
| SCHEMBL20370587 | 0.85 | RAB9A (0.39) | RAB9AFFAR4P2RY14ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, MBD2, PAXBP1 | RAB9A 4014/4885ESR1 426/4885FFAR4 2050/4885 |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | SP1, MBD2, PAXBP1 | RAB9A 4014/4885ESR1 426/4885FFAR4 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.